BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 199 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $8 | -100.0% | 67,300 | -27.3% | 0.00% | -95.2% |
Q3 2022 | $314,000 | -1.9% | 92,634 | +9.8% | 0.02% | +31.2% |
Q2 2022 | $320,000 | -53.4% | 84,357 | -34.9% | 0.02% | -42.9% |
Q1 2022 | $686,000 | -74.3% | 129,536 | -61.4% | 0.03% | -61.6% |
Q4 2021 | $2,671,000 | +15.6% | 335,776 | +33.0% | 0.07% | -2.7% |
Q3 2021 | $2,311,000 | +311.2% | 252,553 | +107.5% | 0.08% | +341.2% |
Q2 2021 | $562,000 | +152.0% | 121,707 | +13.1% | 0.02% | +54.5% |
Q1 2021 | $223,000 | -50.6% | 107,600 | -58.6% | 0.01% | -15.4% |
Q4 2020 | $451,000 | +3369.2% | 259,600 | +1004.7% | 0.01% | +1200.0% |
Q3 2020 | $13,000 | -76.8% | 23,500 | -68.3% | 0.00% | -66.7% |
Q2 2020 | $56,000 | +522.2% | 74,100 | +60.4% | 0.00% | +200.0% |
Q1 2020 | $9,000 | -25.0% | 46,200 | +69.9% | 0.00% | 0.0% |
Q4 2019 | $12,000 | – | 27,200 | +35.3% | 0.00% | – |
Q2 2019 | $0 | -100.0% | 20,100 | -60.9% | 0.00% | -100.0% |
Q4 2016 | $326,000 | – | 51,468 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Burrage Capital Management LLC | 1,105,673 | $8,237,000 | 6.28% |
Sarissa Capital Management LP | 8,175,000 | $60,903,000 | 6.22% |
ORACLE INVESTMENT MANAGEMENT INC | 2,980,870 | $22,207,000 | 2.78% |
DG Capital Management, LLC | 1,075,732 | $8,014,000 | 1.70% |
Ghost Tree Capital, LLC | 900,000 | $6,705,000 | 1.49% |
Parkman Healthcare Partners LLC | 538,370 | $4,011,000 | 1.03% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,835,810 | $43,477,000 | 0.86% |
Formidable Asset Management, LLC | 470,419 | $3,470,000 | 0.80% |
KNOTT DAVID M | 219,461 | $1,635,000 | 0.74% |
Altium Capital Management LP | 250,000 | $1,863,000 | 0.70% |